I ntravenously administered activators of the fibrinolytic system decrease infarct size, improve left ventricular function, and improve survival of patients with acute transmural myocardial infarction, especially when administered early after the onset of symptoms.1 '2 When judged from comparisons of diverse thrombolytic agents, the rapidity and frequency of recana-lization seem greater with second-compared with first-generation agents (i.e., recombinant tissue-type plasminogen activator [rt-PA] compared with streptokinase), perhaps because of the clot specificity of second-generation agents and the more modest systemic plasminemia induced. [1] [2] [3] [4] Nevertheless, failure to induce recanalization is encountered in 15-40% of patients with acute thrombotic occlusion, and early reocclusion occurs in 5-30% of patients in whom recanalization is initially successful. [4] [5] [6] [7] [8] Reocclusion may reflect incomplete lysis and/or continuing thrombosis stimulated by residual highgrade stenosis and residual clot with elaboration of thrombin. Although antithrombin agents such as heparin and antiplatelet agents such as aspirin extend beneficial effects, they may increase the risk of bleeding and are not universally effective in preventing reocclusion.1-8 
Induction of Thrombolysis
To compare the efficacy of hybrid-B and t-PA regarding induction of thrombolysis and maintenance of coronary patency, 23 dogs were anesthetized with the same regimen that was used for studies of half-life. After catheterization of the femoral artery and vein, a modified Amplatz (USCI, Billerica, Mass) catheter was introduced into the left common carotid artery. Arterial pressure and the electrocardiogram were monitored and recorded with a Gould (Centerville, Ohio) two-channel recorder. Before induction of coronary occlusion, a loading dose of 1 mg/kg lidocaine was given intravenously, which was followed by a continuous infusion of 50 gg/kg per minute. No anticoagulants or antiplatelet agents were administered.
A thrombogenic copper coil was used to induce coronary thrombosis, as previously described in detail.12 After control arteriography, a 0.021-in. guide wire was advanced into the left anterior descending coronary artery and the Amplatz catheter was withdrawn. A copper coil (2 mm i.d., 3 mm o.d., 5 mm in length) was advanced over the guide wire with a small flexible catheter until the coil lodged in the left anterior descending coronary artery past the first diagonal branch. The guide wire was then removed, and the intracoronary catheter was positioned 2-3 cm proximal to the coil and used for sequential injections of contrast medium for documentation of occlusion or patency. All arteriograms were obtained by gently injecting [1] [2] 
Thrombolysis
The first eight dogs given Hybrid-B were studied only to evaluate the efficacy of the agent in inducing lysis. In the seven dogs subsequently given Hybrid-B, the time to reocclusion was determined as well. Figure 3 depicts angiograms from one representative animal.
The time to lysis (measured from the onset of drug administration) and the time to reocclusion (measured from the end of infusion) were evaluated with the use of serial arteriograms. Time to lysis was similar, with infusions of Hybrid-B (n= 15) and t-PA (n=8) averaging 54±26 minutes and 64±34 minutes, respectively (Figure 4) Functional activity as a function of time after onset of infusion is shown in Figure 6 . The persistence of functional activity with Hybrid-B compared with t-PA is apparent. Prolongation of the time to reocclusion correlated closely with persistence of functional activity (r= -0.90, p<0.006).
To determine whether the prolonged activity in the blood of Hybrid-B was associated with an increase in systemic fibrinolysis, sequentially obtained blood samples were assayed for fibrinogen and a2-antiplasmin. Despite the relatively high and sustained amounts of Hybrid-B activity, systemic lytic effects were modest (Figure 7) . The nadir values of fibrinogen and a2-antiplasmin were 77±25% and 56±24% of preinfusion values in dogs given Hybrid-B by infusion for 30 minutes, values slightly higher than those observed after infusion of t-PA (66±27 and 37±23%). Concentrations of fibrinogen and of a2-antiplasmin were comparably maintained after bolus administration of Hybrid-B for 1 minute (76±11 and 43±12% of predrug levels, respectively).
Discussion
The results of this study indicate that Hybrid-B, a genetically engineered variant of t-PA that is de- signed to exhibit a prolonged half-life in the circulation, induces prompt, clot-selective coronary thrombolysis and sustained patency. Factors potentially contributing to the prolonged half-life of Hybrid-B compared with that of t-PA include modifications of expression of high mannose residues and conformational differences affecting recognition by hepatic receptors1"'4 ( Figure 1 inserted coils were given 10 mg or less, low peak antigen concentrations or the lack of complete thrombolysis occurred (n=9). With doses of 18 mg (equivalent to the dose of Hybrid-B used), only partial lysis was seen (n =3). With doses of 50 mg given for 1 hour (with 10% as a bolus), thrombolysis was apparently complete, and plasma concentrations of antigen were similar to those seen clinically with doses greater than or equal to 60 mg. Moreover, peak levels of functional activity were roughly equivalent ( Figure  5 ). less, residual stenosis is common after successful thrombolysis in patients and may serve as a somewhat analogous nidus for recurrent thrombosis.
Clinical Implications
The results of this study indicate that the use of Hybrid-B, a novel variant of t-PA constructed to exhibit prolonged clearance from the blood and concomitantly prolonged biological activity, permits prompt induction of coronary thrombolysis with doses markedly lower than those required with t-PA. Furthermore, the genetically engineered variant prolongs the time to reocclusion. Use of more modest doses of plasminogen activators is attractive because it may permit reduction of costs in the clinical setting.
Hybrid-B may permit rapid induction of thrombolysis with sustained patency without the need for prolonged infusions. Its pharmacokinetic profile suggests that a bolus injection may be sufficient to induce lysis promptly in patients because of the high initial concentrations anticipated and the slow clearance. Therefore, treatment may be simplified. Persistence of relatively high concentrations would be anticipated to prevent early reocclusion as well. Despite its prolonged clearance from the circulation, it does not induce systemic lytic effects with therapeutically effective doses. Accordingly, it is a particularly attractive agent for evaluation in patients.
